Non Small Cell Lung Cancer Nsclc Pipeline Insight
DelveInsight’s, “Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Non-Small Cell Lung Cancer Understanding
Non-Small Cell Lung Cancer (NSCLC): Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
The three main histological subtypes of Non-Small Cell Lung Cancer are:
- Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumours start in mucus-producing cells that line the airways.
- Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.
- Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.
Symptoms of lung cancer that are in the chest:
- Coughing, especially if it persists or becomes intense
- Pain in the chest, shoulder, or back unrelated to pain from coughing
- A change in color or volume of sputum
- Shortness of breath
- Changes in the voice or being hoarse
- Harsh sounds with each breath (stridor)
- Recurrent lung problems, such as bronchitis or pneumonia
- Coughing up phlegm or mucus, especially if it is tinged with blood
- Coughing up blood
Tests that examine the lungs are used to diagnose and stage non-small cell lung cancer.
- Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual.
- Laboratory tests: Medical procedures that test samples of tissue, blood, urine, or other substances in the body. These tests help to diagnose disease, plan and check treatment, or monitor the disease over time.
- Chest X-ray
Treatment primarily involves surgery, chemotherapy, or radiation therapy. Because most lung cancers cannot be cured with currently available therapeutic modalities, the appropriate application of skilled palliative care is an important part of the treatment of patients with Non-Small Cell Lung Cancer.
Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Small Cell Lung Cancer Emerging Drugs
Canakinumab is an interleukin (IL)-1β blocker that is being evaluated in CANOPY trial. CANOPY-A is a Phase III multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of canakinumab as adjuvant therapy in adult subjects with stages II-IIIA and NSCLC following complete surgical resection. The primary endpoint is disease-free survival
Cemiplimab (Libtayo)- Regeneron Pharmaceuticals/Sanofi
Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. The open-label, randomized, multi-center Phase 3 trial investigated the first-line treatment of Libtayo monotherapy compared to platinum-doublet chemotherapy in squamous or non-squamous advanced NSCLC that tested positive for PD-L1 in ≥50% of tumor cells. A separate Phase 3 trial evaluating a first-line combination of Libtayo and chemotherapy in patients with advanced NSCLC irrespective of PD-L1 expression is also underway and expected to be fully enrolled in 2020.
Further product details are provided in the report……..
Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Non-Small Cell Lung Cancer
There are approx. 200+ key companies which are developing the therapies for Non-Small Cell Lung Cancer. The companies which have their Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Merck, Eisai, Novartis Pharmaceuticals, Ariad Pharmaceuticals, Takeda, Regeneron Pharmaceuticals, Innovent Biologics etc.
DelveInsight’s report covers around 200+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Gene therapies
- CAR-T Therapies
- Serum globulins
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Small Cell Lung Cancer drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non-Small Cell Lung Cancer.
- August 2020: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion–positive Non-Small Cell Lung Cancer who had previously received platinum-based chemotherapy and those who were previously untreated.
Non-Small Cell Lung Cancer Report Insights
- Non-Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Non-Small Cell Lung Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Non-Small Cell Lung Cancer drugs?
- How many Non-Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Non-Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Millennium Pharmaceuticals, Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Bristol Myers Squibb
- IO Biotech
- Immutep S.A.
- Daiichi Sankyo, Inc.
- Regeneron Pharmaceuticals
- Hanmi Pharmaceutical Company Limited
- TYK Medicines, Inc